Feasibility of using the ARES™ Device to measure sleep in men with prostate cancer starting androgen deprivation therapy

PURPOSE OF THIS STUDY:
To evaluate if the ARES™ device can be used to study the effects of Androgen Deprivation Therapy (ADT) on the sleep patterns of prostate cancer patients.

WHO CAN PARTICIPATE?
Prostate cancer patients who are starting ADT and plan to be receiving treatment for at least 6 months (with or without radiation therapy).

WHAT IS INVOLVED?
Participants will be required to wear the ARES™ device at home to record their sleep at 3 time points: before starting ADT, and at 3 and 6 months after starting ADT. Participants will complete questionnaires at each time point which ask questions about their sleep, hot flashes and quality of life. Body parameters (including weight, height, waist and neck circumferences) will also be measured. At the end of the study, participants will also be asked to complete an exit phone interview to learn about their experiences using the ARES™ device.

CONTACT INFORMATION:
Maria Spillane, Clinical Research Coordinator
Prostate Cancer Supportive Care (PCSC) Program
Vancouver Prostate Centre
Phone: 604.875.4111 ext.62338
Email: mspillane@prostatecentre.com

To learn more about this study, visit vchri.ca/participate

STUDY TIME/DURATION
Ongoing until June 2018

STUDY LOCATION
Study assessments will take place at the VCHRI Clinical Research Unit at the Diamond Health Care Centre. Sleep recordings will be done at home.

PRINCIPAL INVESTIGATOR
Dr. Larry Goldenberg
Professor
Vancouver Prostate Centre
UBC Department of Urologic Sciences

Health research changes lives.
Be part of the discovery.
vchri.ca/participate